Self-organization of living matter into complex structures: How light pattern impacts aggregation of active filaments
When active filaments are exposed to localized illumination, they accumulate into stable structures along the boundaries of ...
Scientists reveal structural basis for precursor protein import into chloroplasts
The TOC (Translocon at the Outer envelope of Chloroplasts)-TIC (Translocon at the Inner envelope of Chloroplasts) ...
Google DeepMind open-sources AlphaFold 3, ushering in a new era for drug discovery and molecular biology
Google DeepMind releases AlphaFold 3's source code to academics, marking a significant advance in AI-powered molecular biology and drug discovery, while balancing open science with commercial ...
The Globe and Mail14d
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Shares of Apellis Pharmaceuticals have been under pressure because investors are concerned about the sales trajectory of its vision preservation treatment, Syfovre. Although Syfovre has been ...
The Motley Fool15d
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...
Investing15d
Citi reiterates Apellis stock as a 'BUY' on transformative pegcetacoplan data
The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.
FiercePharma16d
Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay
While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.